JPRN-UMIN000006243已完成未知
Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A) - Phase II of CBDCA/PEM/BEV for NSCLC with carcinomatous pleuritis
orth-East Japan study group0 个研究点目标入组 30 人开始时间: 2011年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Clinically ineligible interstitial pneumonitis 2. Episode of hemoptysis 3. With brain metastasis, or tumor with large vessel invation or cavity formation 4. With active gastrointestinal ulcer 5. With severe comorbidities 6. With inadequate conditions judged by the attending physician
研究者
相似试验
已完成
2 期
Phase II Study of Carboplatin+Pemetrexed+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC).non-squamous non-small cell lung cancerJPRN-UMIN000003387Kansai Medical University Hirakata Hospital25
已完成
不适用
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)Advanced non-squamous non-small cell lung cancer with EGFR MutationJPRN-UMIN000003737Central Japan Lung Study Group32
已完成
2 期
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer without EGFR Mutation (CJLSG0909)Advanced non-squamous non-small cell lung cancer without EGFR MutationJPRN-UMIN000003736Central Japan Lung Study Group52
已完成
2 期
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27
已完成
2 期
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26